Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Graphite Bio, Inc. (GRPH : NSDQ)
 
 • Company Description   
Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is based in SOUTH SAN FRANCISCO, Calif.

Number of Employees: 69

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.48 Daily Weekly Monthly
20 Day Moving Average: 826,160 shares
Shares Outstanding: 57.97 (millions)
Market Capitalization: $143.77 (millions)
Beta:
52 Week High: $34.00
52 Week Low: $2.19
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.06% -31.03%
12 Week -72.38% -70.03%
Year To Date -80.05% -76.27%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
201 Haskins Way Suite 210
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-484-0886
fax: -
ir@graphitebio.com http://www.graphitebio.com
 
 • General Corporate Information   
Officers
Josh Lehrer - Chief Executive Officer;President and Director
Perry Karsen - Chairman of the Board and Director
Philip P. Gutry - Chief Business Officer; Head of Finance & Investor
Abraham Bassan - Director
Jerel Davis - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 38870X104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 57.97
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $143.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 25.90% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.40
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -37.14%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -20.17
12/31/21 - -24.33
09/30/21 - -
ROA
03/31/22 - -19.42
12/31/21 - -23.48
09/30/21 - -
Current Ratio
03/31/22 - 26.93
12/31/21 - 31.44
09/30/21 - 35.60
Quick Ratio
03/31/22 - 26.93
12/31/21 - 31.44
09/30/21 - 35.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.23
12/31/21 - 6.61
09/30/21 - 6.89
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©